During January, the county Department of Behavioral Wellness joins the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health ...

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc.

In 2019, Jeremy C. spent his days roaming the streets of Las Vegas and frequenting its underground tunnels, a sprawling ...

Young adults were more likely to report low confidence in knowing which coverage-related questions to ask their insurers, and ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportun ...

Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.

An in-depth analysis of PFAS sources, environmental persistence, and health risks, emphasizing the significant role of ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...